Vincenzo Maria Perriello
Overview
Explore the profile of Vincenzo Maria Perriello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Falini B, Sorcini D, Perriello V, Sportoletti P
Leukemia
. 2024 Dec;
39(2):276-290.
PMID: 39690184
The nucleophosmin (NPM1) gene encodes for the most abundant nucleolar protein. Thanks to its property to act as histone chaperone and to shuttle between the nucleus and cytoplasm, the NPM1...
2.
Martarelli N, Capurro M, Mansour G, Jahromi R, Stella A, Rossi R, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000338
Chimeric antigen receptor (CAR) T cells represent a revolutionary immunotherapy that allows specific tumor recognition by a unique single-chain fragment variable (scFv) derived from monoclonal antibodies (mAbs). scFv selection is...
3.
Marra A, Akarca A, Martino G, Ramsay A, Ascani S, Perriello V, et al.
Haematologica
. 2023 Jun;
108(12):3491-3495.
PMID: 37381766
No abstract available.
4.
Perriello V, Falini L, Ruggeri L, Sorcini D, Ballanti S, Flenghi L, et al.
EJHaem
. 2023 May;
4(2):559-562.
PMID: 37206291
No abstract available.
5.
Nagler A, Perriello V, Falini L, Falini B
Br J Haematol
. 2023 Mar;
201(3):396-410.
PMID: 36916189
Chimeric antigen receptor (CAR) T cells targeting CD19 represent a promising salvage immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), offering ~40% of long-term responses. In everyday clinical practice,...
6.
Biondi M, Tettamanti S, Galimberti S, Cerina B, Tomasoni C, Piazza R, et al.
Blood
. 2023 Feb;
141(21):2587-2598.
PMID: 36787509
Acute myeloid leukemia (AML) is a hematological malignancy derived from neoplastic myeloid progenitor cells characterized by abnormal clonal proliferation and differentiation. Although novel therapeutic strategies have recently been introduced, the...
7.
Perriello V, Rotiroti M, Pisani I, Galimberti S, Alberti G, Pianigiani G, et al.
Blood Adv
. 2022 Dec;
7(12):2855-2871.
PMID: 36521101
Acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. Adoptive cell therapy by chimeric antigen receptor (CAR)-engineered T cells demonstrated a high therapeutic potential,...
8.
Perriello V, Falini L, Ruggeri L, Innocente A, Ballanti S, Costa C, et al.
Am J Hematol
. 2022 Nov;
98(1):212-219.
PMID: 36346356
No abstract available.
9.
Ranieri R, Pianigiani G, Sciabolacci S, Perriello V, Marra A, Cardinali V, et al.
Leukemia
. 2022 Aug;
36(10):2351-2367.
PMID: 36008542
Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is predominantly located in the nucleolus and exerts multiple functions, including regulation of centrosome duplication, ribosome biogenesis and export, histone assembly,...
10.
Saldi S, Perriello V, Falini L, Ruggeri L, Fulcheri C, Ciardelli S, et al.
Front Immunol
. 2022 Aug;
13:934700.
PMID: 35911683
CAR T cell therapy has transformed the salvage approach for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Maintaining disease control before CAR T cell infusion during product manufacturing (so-called bridging...